Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

被引：17

作者：

Fernando, Hiran C.

Yang, Jing

Ferraro, Geri L.

Keller, Steven M.

机构：

[1] INOVA Fairfax Med Campus, Dept Surg, Falls Church, VA USA

[2] INOVA Fairfax Med Campus, Dept Thorac Surg, Falls Church, VA USA

[3] Merck & Co Inc, Kenilworth, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS8583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8583

引用

页数：2

共 50 条

[1] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
[2] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[3] A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III STUDY EVALUATING PERIOPERATIVE TORIPALIMAB COMBINED WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY IN RESECTABLE STAGE III NSCLC
Wang, Wenxiang
Wu, Lin
Zhang, Wei
Lu, Shun
Fang, Haohui
Yu, Guohua
Zhou, Ming
Xing, Wenqun
Chen, Qixun
Li, Xingya
Yang, Nong
Ye, Minhua
Fang, Wentao
Huang, Yunchao
Liu, Jichun
Tan, Lijie
Hang, Xiaosheng
Zhang, Wengang
Zhang, Liwei
Chen, Jun
Zhang, Xun
Zhang, Yu
Jiang, Jie
Zhong, Aihong
Li, Shanqing
Liu, Yunpeng
Wu, Guowu
Kang, Xiaoyan
Tian, Ying
Xu, Tao
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A223 - A224
[4] Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study
Tsuboi, M.
Luft, A.
Ursol, G.
Kato, T.
Levchenko, E.
Eigendorff, E.
Berard, H.
Zurawski, B.
Demedts, I.
Garassino, M. C.
Yang, J.
Makarious, K.
Keller, S. M.
Wakelee, H. A.
ANNALS OF ONCOLOGY, 2020, 31 : S801 - S802
[5] KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC
Rudin, C.
Shen, L.
Pietanza, M. C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2400 - S2400
[6] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Gandhi, Leena
Rodgriguez-Abreu, Delvys
Gadgeel, Shirish
Esteban, Emilio
Felip, Enriqueta
De Angelis, Flavia
Domine, Manuel
Clingan, Philip
Hochmair, Maximilian J.
Powell, Steven
Cheng, Susanna Yee-Shan
Bischoff, Helge G.
Peled, Nir
Grossi, Francesco
Jennens, Ross R.
Reck, Martin
Hui, Rina
Garon, Edward B.
Boyer, Michael
Rubio-Viqueira, Belen
Novello, Silvia
Kurata, Takayasu
Gray, Jhanelle E.
Vida, John J.
Wei, Ziwen
Yang, Jing
Raftopoulos, Harry
Pietanza, M. Catherine
Garassino, Marina C.
CANCER RESEARCH, 2018, 78 (13)
[7] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Spicer, Jonathan D.
Garassino, Marina C.
Wakelee, Heather
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
Chen, Ke-Neng
Dooms, Christophe
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston L.
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Arunachalam, Ashwini
Keller, Steven M.
Samkari, Ayman
Gao, Shugeng
LANCET, 2024, 404 (10459): : 1240 - 1252
[8] Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Garassino, Marina Chiara
Wakelee, Heather A.
Spicer, Jonathan
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston L.
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Yang, Jing
Arunachalam, Ashwini
Norquist, Josephine M.
Keller, Steven M.
Gao, Shugeng
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
Cappuzzo, F.
Ciuleanu, T.
Stelmakh, L.
Cicenas, S.
Szczesna, A.
Juhasz, E.
Gonzalez, E. Esteban
Molinier, O.
Klingelschmitt, G.
Giaccone, G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[10] ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC).
Coleman, Robert L.
Oza, Amit M.
Lorusso, Domenica
Aghajanian, Carol
Oaknin, Ana
Dean, Andrew
Colombo, Nicoletta
Weberpals, Johanne I.
Clamp, Andrew
Scambia, Giovanni
Leary, Alexandra
Holloway, Robert W.
O'Malley, David M.
Cameron, Terri
Maloney, Lara
Goble, Sandra
Lin, Kevin
Sun, James
Giordano, Heidi
Ledermann, Jonathan A.
CLINICAL CANCER RESEARCH, 2018, 24 (15) : 30 - +

← 1 2 3 4 5 →